Breaking News, Financial News

Financial Report: Jubilant Life Sciences

Revenue in the quarter up 25%, but earnings fall on INR-USD currency movement

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Jubilant Life Sciences 3Q Revenues: $219.8 million (+25%) 3Q Loss: $15.8 million (earnings were $9.4 million 3Q10) YTD Revenues: $622.9 million (+21%) YTD Earnings: $15.8 million (-56%) Comments: International business grew 28% in the quarter, contributing 71% to sales at $155.1 million. Sales from Regulated Markets of U.S., Canada, Europe and Japan were $128.4 million (+43%), accounting for 58% of sales. YTD International business accounted for $435.0 million (+22%), contributing 70% to sa...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters